Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD for Alcohol Withdrawal
NCT04205682Phase 1Unknown
- Sponsor
- South Western Sydney Local Health District
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in alcohol withdrawal syndrome (AWS) comparing Cannabidiol (CBD) with Placebo (2 arms). Primary endpoint: Diazepam Rescue Medication Use at 5 days. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on NCT04205682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205682.